Author:
Warren Hannah,Olsburgh Jonathon
Abstract
Abstract
Purpose of Review
Renal masses in the kidney graft pose an important clinical dilemma, balancing graft function against the need for cancer control.
Recent Findings
Donor origin cancers in the renal graft can be classified as ‘donor transmitted’ or ‘donor derived’. The landmark TracerX Renal changed our understanding of renal cell carcinoma oncogenesis, demonstrating that key mutations in childhood lead to clinically apparent tumours in later life. Identified pre-operatively, contemporary evidence suggests that masses excised prior to transplantation result in acceptable oncologic safety and graft function. Identified post-operatively management mirrors that for a mass in a solitary kidney in the non-transplant population, with focus on a nephron-sparing approach.
Summary
With growing number of kidney transplants each year, ageing donors, and increasing graft survival, masses in the renal graft are likely to become a more prevalent clinical conundrum.
Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. NHS Blood and Transplant. Organ donation and transplantation: activity report 2017/18. 2018.
2. Desai R, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J. Cancer transmission from organ donors - unavoidable but low risk. Transplantation. 2012;94(12):1200–7.
3. Myron Kauffman H, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation. 2002;74(3):358–62.
4. British Transplantation Society. Guidelines for living donor kidney transplantation. Fourth Edition [Internet]. 2018. Available from: www.bts.org.uk
5. Ploussard G, Chambade D, Meria P, Gaudez F, Tariel E, Verine J, et al. Biopsy-confirmed de novo renal cell carcinoma (RCC) in renal grafts: a single-centre management experience in a 2396 recipient cohort. Br J Urol Int. 2011:195–9.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献